Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Dec 3:339:b4731.
doi: 10.1136/bmj.b4731.

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database

Ioanna Tzoulaki  1 , Mariam Molokhia, Vasa Curcin, Mark P Little, Christopher J Millett, Anthea Ng, Robert I Hughes, Kamlesh Khunti, Martin R Wilkins, Azeem Majeed, Paul Elliott
Affiliations
Comparative Study

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database

Ioanna Tzoulaki et al. BMJ. .

Abstract

Objective: To investigate the risk of incident myocardial infarction, congestive heart failure, and all cause mortality associated with prescription of oral antidiabetes drugs.

Design: Retrospective cohort study.

Setting: UK general practice research database, 1990-2005.

Participants: 91,521 people with diabetes.

Main outcome measures: Incident myocardial infarction, congestive heart failure, and all cause mortality. Person time intervals for drug treatment were categorised by drug class, excluding non-drug intervals and intervals for insulin.

Results: 3588 incident cases of myocardial infarction, 6900 of congestive heart failure, and 18,548 deaths occurred. Compared with metformin, monotherapy with first or second generation sulphonylureas was associated with a significant 24% to 61% excess risk for all cause mortality (P<0.001) and second generation sulphonylureas with an 18% to 30% excess risk for congestive heart failure (P=0.01 and P<0.001). The thiazolidinediones were not associated with risk of myocardial infarction; pioglitazone was associated with a significant 31% to 39% lower risk of all cause mortality (P=0.02 to P<0.001) compared with metformin. Among the thiazolidinediones, rosiglitazone was associated with a 34% to 41% higher risk of all cause mortality (P=0.14 to P=0.01) compared with pioglitazone. A large number of potential confounders were accounted for in the study; however, the possibility of residual confounding or confounding by indication (differences in prognostic factors between drug groups) cannot be excluded.

Conclusions: Our findings suggest a relatively unfavourable risk profile of sulphonylureas compared with metformin for all outcomes examined. Pioglitazone was associated with reduced all cause mortality compared with metformin. Pioglitazone also had a favourable risk profile compared with rosiglitazone; although this requires replication in other studies, it may have implications for prescribing within this class of drugs.

PubMed Disclaimer

Conflict of interest statement

Competing interests: PE is a coprincipal investigator on a grant cofunded by the UK Medical Research Council and GlaxoSmithKline. MRW has received consultancy fees from GlaxoSmithKline in the past five years. MM has received grants from Pfizer, AstraZeneca, and the Serious Adverse Events Consortium (collaboration between industry and academia). KK has acted in a consultant capacity or as a speaker for Novo-Nordisk, Sanofi, Lilli, Merck Sharp & Dohme, Tekeda, GSK, and Bayer and has received research grants from Servier, Novartis, Novo-Nordisk, Sanofi-Aventis, Merck Sharp & Dohme, Pfizer, Bayer, Unilever, and Lilly.

Figures

None
Risk of myocardial infarction, congestive heart failure, and all cause mortality for different comparisons of drug groups. Analysis is stratified by year of prescription and quartiles of age at treatment, and adjusted for sex, duration of diabetes, previous peripheral arterial disease, previous cardiovascular disease, aspirin, statin or fibrate, diuretics, calcium channel blockers, spironolactone, β adrenergic antagonists, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, nitrates, steroids, non-steroidal anti-inflammatory drugs, digoxin, and any previous complications from diabetes (model 2). *Any therapy (monotherapy and combinations). †Other drugs and combinations of any oral antidiabetes drugs excluding rosiglitazone and pioglitazone
See this image and copyright information in PMC

References

    1. World Health Organization. Diabetes. 2008. www.who.int/mediacentre/factsheets/fs312/en/index.html.
    1. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36. - PubMed
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. - PubMed
    1. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35. - PubMed
    1. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81. - PubMed

Publication types

MeSH terms